
## **BOEHRINGER INGELHEIM** RESPIRATORY RESEARCH & DEVELOPMENT TIMELINE



- References:

  1. IMS Health MIDAS®, Top 20 Global Products 2015. December 2015
  2. Safety and Elcacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis. Available at https://clinicaltrials.gov/ct2/show/study/NCT00514683?term=nintedanib+IPF&phase=1&rank=2 [last accessed July 2016]
  3. Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol –fixed-dose combination versus mono-components in COPD (GOLD 2–4), Eur Respir J. 2015;45(4):969–979
  4. Szelfer S, Harper III T, Laki I, et al. Tiotropium and olodaterol –fixed-dose combination versus mono-components in COPD (GOLD 2–4), Eur Respir J. 2015;45(4):969–979
  4. Szelfer S, Harper III T, Laki I, et al. Tiotropium and olodaterol –fixed-dose combination versus mono-components in COPD (GOLD 2–4), Eur Respir J. 2015;45(4):969–979
  4. Szelfer S, Harper III T, Laki I, et al. Tiotropium and olodaterol –fixed-dose combination versus mono-components in COPD (GOLD 2–4), Eur Respir J. 2015;45(4):969–979
  4. Szelfer S, Harper III T, Laki I, et al. Tiotropium and olodaterol –fixed-dose combination versus mono-components in COPD (GOLD 2–4), Eur Respir J. 2015;45(4):969–979
  4. Szelfer S, Harper III T, Laki I, et al. Tiotropium and olodaterol –fixed-dose combination of olodaterol and ologaterol and olodaterol and olodaterol and olodaterol and olodater